(Q40810927)

23 September 2017

The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells (English)

1 reference

23 September 2017

3

1 reference

23 September 2017

Ozbek S

1

1 reference

23 September 2017

Peters M

2

1 reference

23 September 2017

Mann A

4

1 reference

23 September 2017

Blessing M

5

1 reference

23 September 2017

Fischer M

6

1 reference

23 September 2017

Schirmacher P

7

1 reference

23 September 2017

Mackiewicz A

8

1 reference

23 September 2017

Rose-John S

9

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

23 September 2017

1 reference

23 September 2017

20

1 reference

23 September 2017

972-979

1 reference

23 September 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1204180

23 September 2017

0 references

cites work

Rational design of a mouse granulocyte macrophage-colony-stimulating factor receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Anti-CD3-activated killer T cells: Interleukin-6 modulates the induction of major histocompatibility complex-unrestricted cytotoxicity and the expression of genes coding for cytotoxic effector molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Soluble interleukin 6 receptor is biologically active in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Antitumor activity of recombinant interleukin 6 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Paracrine cytokine adjuvants in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Soluble receptors for cytokines and growth factors: generation and biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Experimental and clinical studies of cytokine gene-modified tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

Interleukin-6 in biology and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

A bioactive designer cytokine for human hematopoietic progenitor cell expansion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

Clinical application of IL6 in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

Genetically modified tumour vaccines (GMTV) in melanoma clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

The function of the soluble IL-6 receptor in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16alpha cells) as a tumor vaccine in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204180

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1204180

1 reference

Dimensions Publication ID

23 September 2017

0 references

1 reference